Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: Committee for medicinal products for human use - Caught on Camera

Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease

On Friday, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for Sanofi SA’s (NASDAQ:SNY) Rezurock (belumosudil).

Benzinga · Oct 17, 2025

Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Friday recommending Eli Lilly and Co.’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease in adults with confirmed amyloid pathology who are apolipoprotein E ε4 (ApoE4) heterozygotes or non-carriers.

Benzinga · Jul 25, 2025

EMA's Advisory Committee Recommends Eiger's Zokinvy In Premature Aging Disorder

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending Eiger BioPharmaceuticals Inc's (NASDAQ:EIGR) Zokinvy for Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PL). HGPS and PL are ultra-rare and fatal pediatric diseases that cause dramatically accelerated aging and premature death. The CHMP…

Benzinga · May 20, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

EMA' Advisory Committee Recommends Approval For Roche's Two Cancer Drugs

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended conditional approval for Roche Holdings AG's (OTC:RHHBY) mosunetuzumab for relapsed or refractory (R/R) follicular lymphoma (FL). The opinion covers mosunetuzumab for adult patients who have received at least two prior systemic therapies. The CHMP recommendation is based on…

Benzinga · Apr 22, 2022

Calliditas Expects EMA's CHMP Opinion For Nefecon In Q2

Calliditas Therapeutics AB (NASDAQ:CALT) says that the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) can be expected in Q2 of 2022. In its review of the marketing authorization application (MAA) for Nefecon, the CHMP has informed us that they will issue an…

Benzinga · Mar 22, 2022

EMA's Advisory Committee Does Not Back Orphazyme's Arimoclomol Application

Orphazyme A/S (NASDAQ: ORPH) has been notified by the Committee for Medicinal Products for Human Use (CHMP) of a

Benzinga · Feb 24, 2022

EMA's Advisory Committee Recommends Approval Of Blueprint Medicines' Avapritinib In Blood Disorder

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has

Benzinga · Jan 28, 2022

Read news from The Economist, FT, and more,
with one subscription

CHMP Recommends Pfizer's Paxlovid For Use In Adults With COVID-19

The European Medicines Agency's Committee for Medicinal Products for Human Use has

Benzinga · Jan 27, 2022

Coverage From

Benzinga

People

Hutchinson

38 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

European Medicines Agency

The European Medicines Agency

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.